Is Daclatasvir a suitable substitute for Amphotericin B in the treatment of Mucormycosis when Amphotericin B is scarce?

Pugazhenthan ThangarajuSree Sudha Tanguturi YellaVijayakumar Arumugam RamamurthySivakumar MuthusamyLappathai Habib Mohamed Thameemul AnsariIrfan NavabshanSajitha Venkatesan

Published in: Current drug research reviews (2023)

The binding pattern completely alters the dynamics of the protein, resulting in the breakdown of the fungal wall. The vital protein (1XFF) of Rhizopus oryzae is proposed as a possible protein target for the non-structural protein 5A inhibitor/antiviral drug daclatasvir in this study.

Keyphrases

hepatitis c virus
binding protein
protein protein
amino acid
emergency department
small molecule
transcription factor